Germany · Delayed Price · Currency is EUR Abera Bioscience AB Statistics
Total Valuation
FRA:8WK has a market cap or net worth of EUR 11.01 million. The enterprise value is 8.90 million.
| Market Cap | 11.01M |
| Enterprise Value | 8.90M |
Important Dates
The last earnings date was Thursday, November 20, 2025.
| Earnings Date | Nov 20, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 18.45M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 5.38% |
| Owned by Institutions (%) | n/a |
| Float | 17.45M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 7.04 |
| PB Ratio | 4.33 |
| P/TBV Ratio | 4.33 |
| P/FCF Ratio | 471.68 |
| P/OCF Ratio | 93.75 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -67.64 |
| EV / Sales | 5.65 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 381.20 |
Financial Position
The company has a current ratio of 4.96
| Current Ratio | 4.96 |
| Quick Ratio | 4.17 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -7.94% and return on invested capital (ROIC) is -5.97%.
| Return on Equity (ROE) | -7.94% |
| Return on Assets (ROA) | -4.97% |
| Return on Invested Capital (ROIC) | -5.97% |
| Return on Capital Employed (ROCE) | -6.23% |
| Revenue Per Employee | 312,869 |
| Profits Per Employee | -26,303 |
| Employee Count | 5 |
| Asset Turnover | 0.79 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +66.67% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +66.67% |
| 50-Day Moving Average | 0.55 |
| 200-Day Moving Average | 0.58 |
| Relative Strength Index (RSI) | 51.41 |
| Average Volume (20 Days) | n/a |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, FRA:8WK had revenue of EUR 1.56 million and -131,515 in losses.
| Revenue | 1.56M |
| Gross Profit | 1.56M |
| Operating Income | -158,198 |
| Pretax Income | -131,515 |
| Net Income | -131,515 |
| EBITDA | -144,088 |
| EBIT | -158,198 |
| Earnings Per Share (EPS) | n/a |
Balance Sheet
The company has 2.10 million in cash and n/a in debt, giving a net cash position of 2.10 million.
| Cash & Cash Equivalents | 2.10M |
| Total Debt | n/a |
| Net Cash | 2.10M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 2.54M |
| Book Value Per Share | n/a |
| Working Capital | 2.14M |
Cash Flow
In the last 12 months, operating cash flow was 117,405 and capital expenditures -94,069, giving a free cash flow of 23,336.
| Operating Cash Flow | 117,405 |
| Capital Expenditures | -94,069 |
| Free Cash Flow | 23,336 |
| FCF Per Share | n/a |
Margins
Gross margin is 100.00%, with operating and profit margins of -10.11% and -8.41%.
| Gross Margin | 100.00% |
| Operating Margin | -10.11% |
| Pretax Margin | -8.41% |
| Profit Margin | -8.41% |
| EBITDA Margin | -9.21% |
| EBIT Margin | -10.11% |
| FCF Margin | 1.49% |
Dividends & Yields
FRA:8WK does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -1.19% |
| FCF Yield | 0.21% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |